We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Procarbazine, prednisolone and cyclophosphamide oral combination chemotherapy protocol for canine lymphoma.
- Authors
O'Connell, Kathleen; Thomson, Maurine; Morgan, Elizabeth; Henning, Joerg
- Abstract
Orally administered daily chemotherapy offers a novel treatment approach for canine lymphoma in a population of dogs that have failed or not tolerated maximum tolerable dose chemotherapy. A multidrug oral chemotherapy protocol was designed and implemented for the treatment of 50 dogs with multicentric lymphoma with minimal side effects. The protocol consisted of oral procarbazine, prednisolone and cyclophosphamide (PPC) administered daily. Efficacy and toxicity were evaluated by clinical and laboratory evaluation. An overall response rate of 70% was achieved, with 24% and 46% of dogs having a partial and complete response, respectively, to treatment with the PPC protocol. Response to the PPC protocol (complete or partial) and age were the only factors identified as prognostic for time from initiation of the PPC chemotherapy until death. Overall, the protocol was very well tolerated with only one dog requiring protocol discontinuation due to grade 4 thrombocytopenia. Eight dogs recorded gastrointestinal toxicities, seven grade I and one grade II toxicity. These findings demonstrate that the administration of a continuous oral combination chemotherapy can provide comparable survival times in the rescue setting in dogs with multicentric lymphoma with minimal side effects.
- Subjects
COMBINATION drug therapy; PREDNISOLONE; LYMPHOMAS; RESCUE dogs; CYCLOPHOSPHAMIDE
- Publication
Veterinary & Comparative Oncology, 2022, Vol 20, Issue 3, p613
- ISSN
1476-5810
- Publication type
Article
- DOI
10.1111/vco.12814